Skip to main content
Caplight Logo









Atlas Molecular Pharma

Atlas Molecular Pharma

Private
DerioHealthcare & Life Scienceshttps://atlasmolecularpharma.com/

Last Round

Grant

Jun 17, 2025

Total Funding Raised

$2.5M

Company Overview

Atlas Molecular Pharma is a biotechnology company that discovers and develops first-in-class, innovative therapeutics for the treatment of rare and ultra-rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

rare diseasespharmacological chaperonesorphan drugssmall molecule drugsbiotech licensingdrug discoverydrug discovery platformdrug developmentultra-rare diseasesprotein stabilizationclinical stage biotechNMR-based screeningR&D biotechbiopharmaout-licensingfirst-in-class therapeuticsPorphyria treatmentPrion disease therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Atlas Molecular Pharma Comparables

Compare Atlas Molecular Pharma with similar companies based on industry and business-model similarity.

Atlas Molecular Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Protego Biopharma
82%
Pluvia Biotech
81%
Stablix
78%

Atlas Molecular Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 17, 2025
VC RoundFeb 2, 2022
SeedSep 13, 2016

Key People

Founding team and executive leadership

Susana Castel

CEO

Executive Team

Joaquín Castilla

Chief Technology Officer (CTO)

Executive Team

Anna Puigdollers

CFO

Executive Team

Cristina Garrido

Chief Operating Officer (COO). Operations Director

Executive Team

Atlas Molecular Pharma Investors

Notable investors and investment history

Atlas Molecular Pharma investors
InvestorRounds
InvereadyVC Round
Center for Technological Development and InnovationVC Round
CRB Health TechVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 24, 2026

    Monthly visitors grew 34% MoM, reaching 1.4K.

  • Feb 23, 2026

    Grew 57% QoQ from 7 to 11 employees.

Atlas Molecular Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Atlas Molecular Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Atlas Molecular Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersDerio
Employee Range11
Year Founded2015
Last FundingJun 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?